Shukra Pharmaceuticals Limited Share Price

Equities

SHUKRAPHAR6

INE551C01028

Pharmaceuticals

Delayed Bombay S.E. 01:48:37 18/06/2024 pm IST 5-day change 1st Jan Change
122.1 INR +4.99% Intraday chart for Shukra Pharmaceuticals Limited +21.43% +294.67%
Sales 2022 205M 2.46M Sales 2023 595M 7.13M Capitalization 514M 6.17M
Net income 2022 7M 83.93K Net income 2023 44M 528K EV / Sales 2022 0.62 x
Net Debt 2022 32.91M 395K Net Debt 2023 11.08M 133K EV / Sales 2023 0.88 x
P/E ratio 2022
12.6 x
P/E ratio 2023
1.79 x
Employees 182
Yield 2022
0.83%
Yield 2023
1.07%
Free-Float 42.7%
More Fundamentals * Assessed data
Dynamic Chart
Shukra Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2023- 24 CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Shukra Pharmaceuticals Limited Announces the Resignation of Jivansingh Gangasingh Negi as Independent Director CI
Shukra Pharmaceuticals Limited Announces Board Changes CI
Shukra Pharmaceuticals Limited Announces Directorate Resignations CI
Shukra Pharmaceuticals Limited Announces Executive Changes CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended June 30, 2023 CI
Shukra Pharmaceuticals Limited Announces Resignation of Ashvin Trivedi as Non- Executive Director, Effective August 12, 2023 CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2023 CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023 CI
Shukra Pharmaceuticals Limited Recommends Final Dividend for the Financial Year 2023 CI
Shukra Pharmaceuticals Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022 CI
Shukra Pharmaceuticals Limited Announces Board Changes CI
More news
1 day+4.99%
1 week+21.43%
Current month+21.07%
1 month+1.21%
3 months+71.10%
6 months+305.99%
Current year+294.67%
More quotes
1 week
105.55
Extreme 105.55
122.10
1 month
90.00
Extreme 90
122.10
Current year
30.75
Extreme 30.75
122.10
1 year
20.43
Extreme 20.425
122.10
3 years
10.44
Extreme 10.44
122.10
5 years
6.16
Extreme 6.1625
122.10
10 years
6.16
Extreme 6.1625
122.10
More quotes
Managers TitleAgeSince
Director of Finance/CFO 27 11/20/11
Chairman 51 26/12/26
Compliance Officer - -
Members of the board TitleAgeSince
Chairman 51 26/12/26
Director/Board Member 43 23/12/23
Director/Board Member - 12/23/12
More insiders
Date Price Change Volume
18/24/18 122.1 +4.99% 43 633
14/24/14 116.3 +4.96% 9,135
13/24/13 110.8 +4.97% 7,403
12/24/12 105.6 +4.97% 2,998
11/24/11 100.6 +4.96% 1,424

Delayed Quote Bombay S.E., June 18, 2024 at 01:48 pm IST

More quotes
Shukra Pharmaceuticals Limited is an India-based company, which is engaged primarily in the business of manufacturing and marketing of pharmaceutical products. The Company operates in two sectors: pharmaceutical and laboratory. The Company's manufacturing plant is situated in Rakanpur, Gandhinagar. The Company's product portfolio includes antibiotics (penicillin), anti-biotics (cephalosporin), anti-biotics, macrolides, quinolones, anti-bacterial, anti-fungal, anti-malarial, anti-viral, anti-protozoal, anti-anthelmintic, sedative and tranquillizer, anti-depressant, anti-manic, anti-emetic, anti-ulcer, beta blockers, diuretics, analgesic, analgesic (NASID), muscle relaxants, anti-tuberculosis, vitamin products, anti-allergic, corticosteroids, hyper and hypoglycemic. The Company is engaged in manufacturing general formulations, such as tablets, capsules and small volume parenteral.
More about the company
  1. Stock Market
  2. Equities
  3. SHUKRAPHAR6 Stock